Literature DB >> 28851122

Echovirus plays major roles in the natural recombination of Coxsackievirus B3.

Hongxing Shen1, Tingjun Liu1, Yucheng Luo2, Shihe Shao1, Xintao Deng2, Hua Wang1.   

Abstract

Coxsakievirus B3 (CVB3) is a member of enterovirus B (EVB) group, which can cause serious heart diseases such as viral myocarditis. In order to analyze the evolution of CVB3, we performed a recombination analysis of all viral genomes of enterovirus B, and found that there were 19 putative recombination events that produced CVB3. A total of 11 serotypes were found to be involved in the generation of CVB3 progeny virus. These recombination events involved echovirus, EcoV (which includes EcoV6, EcoV9, EcoV14, EcoV15, EcoV17, EcoV21, EcoV24, and EcoV25), CVB4, CVB5, and EVB81, as major or minor parents. The most active, EcoV, which was involved in the 14 of 19 recombination events, acts as one of the parental viruses for CVB3 strains among molecular evolution and recombination events in circulating CVB3. Our study indicates that, EcoV plays major roles in CVB3 recombination, and is involved in the production of 11 new CVB3 recombinant strains.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  CVB3; EcoV; coxsackievirus B3; echovirus; recombination

Mesh:

Year:  2017        PMID: 28851122     DOI: 10.1002/jmv.24929

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  2 in total

1.  Whole-genome analysis of coxsackievirus B3 reflects its genetic diversity in China and worldwide.

Authors:  Qian Yang; Dongmei Yan; Yang Song; Shuangli Zhu; Yun He; Zhenzhi Han; Dongyan Wang; Tianjiao Ji; Yong Zhang; Wenbo Xu
Journal:  Virol J       Date:  2022-04-18       Impact factor: 5.913

2.  Genetic characterization of a novel recombinant echovirus 30 strain causing a regional epidemic of aseptic meningitis in Hokkaido, Japan, 2017.

Authors:  Masahiro Miyoshi; Akiko Goto; Rika Komagome; Hiroki Yamaguchi; Yuji Maruo; Masanori Nakanishi; Setsuko Ishida; Hideki Nagano; Takahisa Sugisawa; Motohiko Okano
Journal:  Arch Virol       Date:  2019-12-11       Impact factor: 2.574

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.